Lung Cancer

VISION Trial Produces Positive Data in NSCLC With MET Exon 14 Mutations

July 03, 2020

Xiuning Le, MD, PhD, discusses the results of tepotinib in patients with advanced non-small cell lung cancer and a MET exon 14 skipping mutation.

Positive Tepotinib Data Underscore Value of Liquid Biopsies in Non-Small Cell Lung Cancer

July 01, 2020

In an interview with Targeted Oncology, Xiuning Le, MD, PhD, discussed the results of the phase II VISION study, which evaluated tepotinib in patients with advanced non-small cell lung cancer and harbor the MET exon 14 skipping mutation. She also highlighted the role of liquid biopsy in this space.

HITTING THE TARGET: Multigene Tests Gain Foothold in More Clinical Settings

June 29, 2020

Broad adoption of testing methods that allow for assessing all possible actionable targets and diagnostic markers in advanced cancer is becoming more complex with greater availability of lifesaving targeted therapies.

Taletrectinib Shows Preliminary Efficacy in Crizotinib-Refractory ROS1+ NSCLC

June 26, 2020

"Taletrectinib is a promising oral tyrosine kinase inhibitor highly selective for ROS1/NTRK mutations with potent activity against ROS1 resistance mutations like G2032R."

CheckMate 227 Induced Manageable Toxicities With Immunotherapy Combination in NSCLC

June 26, 2020

Suresh Ramalingam, MD, FASCO, discusses the key takeaways regarding the toxicities observed in the phase 3 CheckMate 227 clinical trial, which evaluated immunotherapeutic agents nivolumab plus ipilimumab as treatment of patients with non–small cell lung cancer.

Bemcentinib Induces Promising Activity With Pembrolizumab in cAXL-Positive NSCLC

June 25, 2020

"This interim clinical and translational data add further confidence to the potential patient benefit of selective AXL inhibition with bemcentinib, to reverse resistance to immune checkpoint inhibitors in selected cAXL-positive patients who have relapsed on immunotherapy."

Annamycin Demonstrates Efficacy for Lung Metastases in Preclinical Data

June 25, 2020

"In the case of sarcomas treated with the current standard of care, doxorubicin, tumors may be initially responsive in their primary location, but become unresponsive after metastasis to the lungs, which eventually becomes the most likely cause of patients' death."

Immunotherapy Combinations Provide Long-Term Benefit in Stage IV NSCLC

June 17, 2020

In an interview with Targeted Oncology, Suresh Ramalingam, MD, FASCO, discussed the findings from the CheckMate 227 study that support the FDA’s approval of the combination of nivolumab and ipilimumab in patients with advanced NSCLC.

FDA Accelerates Approval of Lurbinectedin in Metastatic SCLC

June 15, 2020

"We are pleased to bring a new treatment choice to relapsed SCLC patients."

Individualizing Immunotherapy in Non–Small Cell Lung Cancer

June 15, 2020

Community physician Jason Williams, MD, DABR, talks to academic oncologist George R. Simon, MD, FACO, FCCP, for an episode of Targeted Talks.